Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Z-VAD-FMK | 187389-52-2 | sc-3067 | 500 µg | $75.00 | 256 | |
A pan-caspase inhibitor that can interfere with downstream apoptosis, potentially impacting the activity of EGL-1. | ||||||
Q-VD-OPH | 1135695-98-5 | sc-222230 | 5 mg | $782.00 | 5 | |
Inhibits a broad range of caspases, potentially impacting apoptosis and processes related to EGL-1 function. | ||||||
Bcl-2 Inhibitor II, YC137 | 810659-53-1 | sc-221287 | 5 mg | $208.00 | 1 | |
Targets the Bcl-2 protein, a homologue of CED-9, and could indirectly affect EGL-1's function. | ||||||
ABT 737 | 852808-04-9 | sc-207242 | 2.5 mg | $204.00 | 54 | |
Binds to Bcl-2 and related proteins, thus might indirectly affect EGL-1's apoptotic activity. | ||||||
Mdivi-1 | 338967-87-6 | sc-215291 sc-215291B sc-215291A sc-215291C | 5 mg 10 mg 25 mg 50 mg | $67.00 $126.00 $251.00 $465.00 | 13 | |
Inhibits mitochondrial division, influencing apoptosis and potentially the broader pathway involving EGL-1. | ||||||
Necrostatin-1 | 4311-88-0 | sc-200142 sc-200142A | 20 mg 100 mg | $94.00 $343.00 | 97 | |
Inhibits necroptosis, another form of cell death, and can influence the cellular environment in which EGL-1 operates. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor that can affect apoptotic signaling, potentially impacting EGL-1 related pathways. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
Inhibits the MAPK/ERK pathway, which is involved in apoptosis regulation, and might indirectly influence EGL-1. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
P38 MAPK inhibitor that affects apoptotic signaling, which could influence EGL-1's function. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
PI3K inhibitor which affects multiple cell survival pathways, potentially impacting EGL-1 related processes. | ||||||